Cereno Scientific AB Logo

Cereno Scientific AB

Clinical-stage biotech developing drugs for rare cardiovascular & pulmonary diseases.

CRNO | ST

Overview

Corporate Details

ISIN(s):
SE0008241541 (+3 more)
LEI:
549300VX8KTMYDS6NM84
Country:
Sweden
Address:
BioVentureHub, 431 83 Mölndal

Description

Cereno Scientific is a clinical-stage biotechnology company developing disease-modifying therapeutics for rare cardiovascular and pulmonary diseases. The company's pipeline focuses on epigenetic modulation and includes a portfolio of Histone Deacetylase (HDAC) inhibitors in clinical development. These candidates are designed to address the root mechanisms of complex diseases. In the preclinical stage, the company is advancing assets such as CS585, a novel prostacyclin (IP) receptor agonist. The strategic focus on rare diseases targets underserved patient populations with significant unmet medical needs, aiming to provide high treatment value and potentially enable shorter development timelines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cereno Scientific AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cereno Scientific AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cereno Scientific AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-16 Sten Sörensen Other Other 866,665 86,666.50 SEK
2024-11-25 Security Holding Sverige AB Other Buy 20,000 99,800.00 SEK

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops IgY-based immune antibodies as alternatives to vaccines and antibiotics.
South Korea
179530
ADC Therapeutics SA Logo
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
A clinical-stage biopharma developing genetically targeted therapies for addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Develops allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
Biopharmaceutical company that develops and manufactures plasma-derived biologics.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
A clinical-stage company developing gene therapies for ocular diseases.
United States of America
ADVM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.